Form 4 for ENTX Entera Bio Ltd.

Accepted 2025-07-18 00:00:00 ET · period of report 2025-07-16 · accession 0001178913-25-002412 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2025-07-18	2025-07-16	ENTX	Burshtein Gregory	Chief of R, D	A - Grant	$0.00	+26.3K	101.4K	+35%	$0
D	2025-07-18	2025-07-16	ENTX	Burshtein Gregory	Chief of R, D	A - Grant	$0.00	+200.0K	200.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Ordinary Shares, par value NIS 0.0000769 per share	2025-07-16	A	A	26,316	$0.00	101,442	D	—	—	(F1) Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2024 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.
2	Derivative	Stock Option (right to buy)	2025-07-16	A	A	200,000	$0.00	200,000	D	$2.28 · — to 2035-04-28	200,000 Ordinary Shares, par value NIS 0.0000769 per share	(F2) This grant of options was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.